Pharmaceutical NPD investment process: Use of accounting information - Case Pharma

 |  Login

Show simple item record

dc.contributor Aalto-yliopisto fi
dc.contributor Aalto University en
dc.contributor.author Wäck, Anna
dc.date.accessioned 2014-08-06T08:38:15Z
dc.date.available 2014-08-06T08:38:15Z
dc.date.issued 2014
dc.identifier.uri https://aaltodoc.aalto.fi/handle/123456789/13654
dc.description.abstract OBJECTIVES OF THE STUDY: The objective of this research is to explore the theory-based suggestions of Hall (2010) regarding the motives for managerial use of accounting information in an empirical setting. Furthermore, the study seeks to fill the prevalent gap in the academic literature by providing insight in the way in which accounting information is used in the NPD investment processes. DATA AND METHODOLOGY: The method used in the research is an in-depth case study. The case company is a European pharmaceutical company. The data consists of nine in-depth semi-structured interviews conducted in 2013 in different organizational functions. In addition, the source material includes a pre-study including five interviews structured around the same themes within the company as well as other public and internal material. FINDINGS OF THE STUDY: The findings indicate that in the early stages of the investment process use of accounting information is only marginal but it increases as the investment process moves forward. The primary benefits of accounting information vis-à-vis other information derive from its role as a facilitator of discussion. Thereby it permits managers to move forward with the investment process even while surrounded by high levels of complexity and uncertainty. However, the findings contrast Hall's propositions as the diversity of operational factors and managerial backgrounds as well as the extent of cross functional communication are not directly proportional to the degree of use of accounting information. en
dc.format.extent 78
dc.language.iso en en
dc.title Pharmaceutical NPD investment process: Use of accounting information - Case Pharma en
dc.type G2 Pro gradu, diplomityö fi
dc.contributor.school Kauppakorkeakoulu fi
dc.contributor.school School of Business en
dc.contributor.department Laskentatoimen laitos fi
dc.contributor.department Department of Accounting en
dc.subject.keyword formal accounting information
dc.subject.keyword informal accounting information
dc.subject.keyword new product development investment
dc.subject.keyword investment decision-making
dc.subject.keyword proprietary drug research
dc.identifier.urn URN:NBN:fi:aalto-201408062318
dc.type.dcmitype text en
dc.programme.major Accounting en
dc.programme.major Laskentatoimi fi
dc.type.ontasot Master's thesis en
dc.type.ontasot Pro gradu tutkielma fi
dc.subject.helecon laskentatoimi
dc.subject.helecon accounting
dc.subject.helecon informaatio
dc.subject.helecon information
dc.subject.helecon tieto
dc.subject.helecon knowledge
dc.subject.helecon investoinnit
dc.subject.helecon investment
dc.subject.helecon päätöksenteko
dc.subject.helecon decision making
dc.subject.helecon tuotekehitys
dc.subject.helecon product development
dc.subject.helecon lääketeollisuus
dc.subject.helecon pharmaceutical industry
dc.subject.helecon terveystalous
dc.subject.helecon health economics
dc.ethesisid 13613
dc.date.dateaccepted 2014-04-11
dc.location P1 I fi


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search archive


Advanced Search

article-iconSubmit a publication

Browse

My Account